Human protein(peptidylprolyl cis/trans isomerase)NIMA-interacting 1,PIN1 ELISA Kit

Product Code	CSB-E11308h
Abbreviation	PIN1
Protein Biological Process 1	Cell Cycle
Target Name	peptidylprolyl cis/trans isomerase, NIMA-interacting 1
Uniprot No.	Q13526
Alias	DOD, UBL5, peptidyl-prolyl cis/trans isomerase, NIMA-interacting|prolyl isomerase|protein (peptidyl-prolyl cis/trans isomerase) NIMA-interacting 1|protein (peptidylprolyl cis/trans isomerase) NIMA-i
Product Type	ELISA Kit
Immunogen Species	Homo sapiens (Human)
Protein Biological Process 3	Cell cycle
Sample Types	serum, plasma, urine, tissue homogenates
Detection Range	1.56 pg/mL-100 pg/mL
Sensitivity	0.39 pg/mL
Assay Time	1-5h
Sample Volume	50-100ul
Detection Wavelength	450 nm
Lead Time	3-5 working days after you place the order, and it takes another 3-5 days for delivery via DHL or FedEx.
Research Area	Neuroscience
Gene Names	PIN1
Tag Info	quantitative
Protein Description	Sandwich
Description	This human PIN1 ELISA kit employs the quantitative sandwich enzyme immunoassay technique to measure the levels of human PIN1 in multiple samples, including serum, plasma, urine, or tissue homogenates. It also uses the enzyme-substrate chromogenic reaction to visualize and analyze the analyte levels through the color intensity. The intensity of the colored product is in direct proportion to the PIN1 levels in the sample and is measured at 450 nm through a microplate reader. PIN1 specifically binds and isomerizes the phosphorylated

serine/threonine–proline motif, which leads to the alteration of protein structure, function, and stability. The altered structure and function of these phosphorylated proteins regulated by PIN1 are closely related to cancer development. PIN1 participates in cellular processes such as the cell cycle, the folding of newly synthesized proteins, responses to DNA damage and stress, and immune responses. PIN1 is highly expressed in human cancers, including prostate cancer, breast cancer, and oral squamous carcinomas. PIN1 drives tumor progression and is negatively associated with clinical outcomes in patients with cancer.

Product Precision

Intra-assay Precision (Precision within an assay): CV%<8%

Three samples of known concentration were tested twenty times on one plate to assess.

Inter-assay Precision (Precision between assays): CV%<10%

Three samples of known concentration were tested in twenty assays to assess.

Linearity

To assess the linearity of the assay, samples were spiked with high concentrations of human PIN1 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.

?	Sample	Serum(n=4)
1:20	Average %	96
	Range %	92-104
1:40	Average %	98
	Range %	92-104
1:80	Average %	102
	Range %	98-108
1:160	Average %	89
	Range %	83-96

Recovery

The recovery of human PIN1 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.

Sample Type	Average % Recovery	Range
Serum (n=5)	95	89-99
EDTA plasma (n=4)	101	96-105

Typical

These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.



pg/ml	OD1	OD2	Average	Corrected
100	2.563	2.462	2.513	2.388
50	2.003	2.104	2.054	1.929
25	1.500	1.511	1.506	1.381
12.5	1.043	1.054	1.049	0.924
6.25	0.624	0.613	0.619	0.494
3.12	0.371	0.360	0.366	0.241
1.56	0.244	0.238	0.241	0.116
0	0.125	0.124	0.125	?

Msds

{"0":{"fileurl":"https://www.cusabio.com/uploadfile/msds/MSDS CSB-E11308h.pdf","filename":"MSDS"}}